CN101151018A - 眼科组合物及其使用方法 - Google Patents

眼科组合物及其使用方法 Download PDF

Info

Publication number
CN101151018A
CN101151018A CNA2006800074102A CN200680007410A CN101151018A CN 101151018 A CN101151018 A CN 101151018A CN A2006800074102 A CNA2006800074102 A CN A2006800074102A CN 200680007410 A CN200680007410 A CN 200680007410A CN 101151018 A CN101151018 A CN 101151018A
Authority
CN
China
Prior art keywords
concentration
pharmaceutical composition
agent
preparation
varies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800074102A
Other languages
English (en)
Chinese (zh)
Inventor
W·卡蒂布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Thea SAS
Original Assignee
Laboratoires Thea SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Thea SAS filed Critical Laboratoires Thea SAS
Publication of CN101151018A publication Critical patent/CN101151018A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2006800074102A 2005-03-09 2006-03-09 眼科组合物及其使用方法 Pending CN101151018A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0502357 2005-03-09
FR0502357A FR2882930B1 (fr) 2005-03-09 2005-03-09 Nouvelles compositions ophtalmologiques et leur mode d'utilisation

Publications (1)

Publication Number Publication Date
CN101151018A true CN101151018A (zh) 2008-03-26

Family

ID=35058756

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800074102A Pending CN101151018A (zh) 2005-03-09 2006-03-09 眼科组合物及其使用方法

Country Status (27)

Country Link
US (2) US20080194649A1 (enExample)
EP (1) EP1858481B1 (enExample)
JP (1) JP2008532985A (enExample)
KR (1) KR20070111501A (enExample)
CN (1) CN101151018A (enExample)
BE (1) BE2019C013I2 (enExample)
CA (1) CA2598503C (enExample)
CY (2) CY1121865T1 (enExample)
DK (1) DK1858481T3 (enExample)
ES (1) ES2728071T3 (enExample)
FR (1) FR2882930B1 (enExample)
HR (1) HRP20191044T1 (enExample)
HU (1) HUE043668T2 (enExample)
IL (1) IL185197A0 (enExample)
LT (2) LT1858481T (enExample)
LU (1) LUC00136I2 (enExample)
MA (1) MA29269B1 (enExample)
MX (1) MX2007010295A (enExample)
NL (1) NL301017I2 (enExample)
NO (2) NO339793B1 (enExample)
PL (1) PL1858481T3 (enExample)
PT (1) PT1858481T (enExample)
RU (1) RU2392925C2 (enExample)
SI (1) SI1858481T1 (enExample)
TN (1) TNSN07343A1 (enExample)
TR (1) TR201908487T4 (enExample)
WO (1) WO2006095095A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159672A (zh) * 2012-07-16 2013-06-19 湖南尔文生物科技有限公司 一种托品酰胺的制备方法
CN105213418A (zh) * 2015-11-11 2016-01-06 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
WO2012111029A2 (en) * 2011-02-18 2012-08-23 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
ITPA20110004A1 (it) * 2011-02-23 2012-08-24 Francesco Paolo Montalto Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi).
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
RU2525512C1 (ru) * 2013-03-28 2014-08-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации
KR20160070077A (ko) * 2013-10-03 2016-06-17 임프리미스 파마슈티컬스 인코포레이티드 안구내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조 방법
US20210346318A1 (en) * 2013-10-03 2021-11-11 Harrow Ip, Llc Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
EP3503873A4 (en) * 2016-08-25 2020-04-15 Harrow IP, LLC EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF
RU2649534C1 (ru) * 2017-05-10 2018-04-03 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ анестезии при факоэмульсификации катаракты
RU2662423C1 (ru) * 2017-07-26 2018-07-25 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ проведения обезболивания при выполнении витреоретинальных операций
BR112021019039A2 (pt) * 2019-03-26 2021-11-30 Martin Uram Composição anestésica e método de anestesia do olho

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026323A (en) * 1960-03-22 1962-03-20 Rubin J Schacter Salts of tribasic acids
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
JPH0780760B2 (ja) * 1986-07-28 1995-08-30 ライオン株式会社 安定化されたフエニレフリン系液剤
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
US6319240B1 (en) * 1999-05-25 2001-11-20 Iomed, Inc. Methods and apparatus for ocular iontophoresis
WO2001034088A2 (en) * 1999-11-12 2001-05-17 Leo Rubin Cardiac device for electrical and chemical regulation, and vasoactive intestinal peptide for treatment of cardiopulmonary disorders
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP4150846B2 (ja) * 2001-03-28 2008-09-17 参天製薬株式会社 ステロイドを有効成分とする網脈絡膜疾患治療剤
RU2183115C1 (ru) * 2001-06-29 2002-06-10 Государственное унитарное предприятие Межбольничная аптека Медицинского центра Управления делами Президента Российской Федерации Фармацевтическая композиция, обладающая спазмолитическим и анальгезирующим действием
US20040013729A1 (en) * 2002-07-18 2004-01-22 Buono Lawrence M. Single-drop multiple-agent composition for topical delivery to the eye
AU2003261304A1 (en) * 2002-07-30 2004-02-16 Omeros Corporation Ophthalmologic irrigation solutions and method

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159672A (zh) * 2012-07-16 2013-06-19 湖南尔文生物科技有限公司 一种托品酰胺的制备方法
CN105213418A (zh) * 2015-11-11 2016-01-06 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法
CN105213418B (zh) * 2015-11-11 2019-01-22 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法

Also Published As

Publication number Publication date
CA2598503C (fr) 2014-01-28
ES2728071T3 (es) 2019-10-22
NL301017I1 (nl) 2019-11-06
EP1858481A1 (fr) 2007-11-28
FR2882930B1 (fr) 2009-03-27
CY1121865T1 (el) 2020-05-29
HRP20191044T1 (hr) 2019-09-06
LT1858481T (lt) 2019-07-10
NO2017008I2 (no) 2017-03-24
CY2019042I1 (el) 2020-05-29
DK1858481T3 (da) 2019-06-03
WO2006095095A1 (fr) 2006-09-14
US20120220637A1 (en) 2012-08-30
PL1858481T3 (pl) 2019-09-30
SI1858481T1 (sl) 2019-08-30
HUE043668T2 (hu) 2019-08-28
LTPA2019017I1 (lt) 2019-12-10
IL185197A0 (en) 2008-01-06
CA2598503A1 (fr) 2006-09-14
NO2017008I1 (no) 2017-03-24
RU2007137115A (ru) 2009-04-20
TR201908487T4 (tr) 2019-07-22
RU2392925C2 (ru) 2010-06-27
US20080194649A1 (en) 2008-08-14
TNSN07343A1 (fr) 2008-12-31
MA29269B1 (fr) 2008-02-01
LUC00136I2 (enExample) 2021-02-12
KR20070111501A (ko) 2007-11-21
MX2007010295A (es) 2007-12-11
CY2019042I2 (el) 2020-05-29
NL301017I2 (nl) 2020-04-30
US9289399B2 (en) 2016-03-22
NO20074850L (no) 2007-09-24
BE2019C013I2 (enExample) 2025-12-03
BRPI0607416A2 (pt) 2009-09-08
JP2008532985A (ja) 2008-08-21
NO339793B1 (no) 2017-01-30
FR2882930A1 (fr) 2006-09-15
PT1858481T (pt) 2019-06-14
LUC00136I1 (enExample) 2019-11-04
EP1858481B1 (fr) 2019-05-08

Similar Documents

Publication Publication Date Title
US9289399B2 (en) Ophthalmologic compositions and use mode thereof
CA2423354C (en) Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
ES2882116T3 (es) Composición farmacéutica de tramadol para uso oftálmico
CN104822265A (zh) 稳定的不含防腐剂的瞳孔散大剂和用于注射的抗炎溶液
BR102014025307A2 (pt) composição farmacêutica de ibuprofeno e tramadol para uso oftálmico
Goldberg The diagnosis and treatment of sickled erythrocytes in human hyphemas
WO2001087304A1 (en) Ophthalmic solution
JP2002527382A (ja) ヒストクロームおよびその眼科治療における使用
US9901627B2 (en) Topical ocular preparation of botulinum toxin for use in ocular surface disease
JPS588013A (ja) 緑内障および高眼圧症の治療用薬学的調合物
JP2009528390A (ja) 薬用ラトランキュリン製剤
US20210346318A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US11484580B2 (en) Topical ocular preparation of botulinum toxin for use in ocular surface disease
JPS63502270A (ja) 散瞳作用を有する眼科用医薬組成物
HK1118211A (en) Ophthalmologic compositions and use mode thereof
JP3579063B2 (ja) 緑内障の治療に有用な薬剤の製造のためのｘ−ａｒｇ−ｇｌｙ−ａｓｐ−ｙの使用法
Sarkar et al. Minimizing Topical Medication in Cataract Surgery
JPH08301785A (ja) 術後乱視予防剤
BRPI0607416B1 (pt) Composição farmacêutica para administração intracameral compreendendo uma combinação de agentes parasimpatolítico, simpatomimético e anestésico local, e uso da mesma na preparação de medicamento
JPH08325143A (ja) 角膜実質損傷治療剤
EP0456988B1 (en) Use of naproxen as mydriatic agent
AU2023255001A1 (en) Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin
JP2000319194A (ja) 乾性角膜症治療剤
Franks et al. Perfluoropropane
McLure Pharmacology for ophthalmic local anaesthesia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1118211

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080326

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1118211

Country of ref document: HK